Valneva SE (INRLF)
OTC GREY OTC GREY Primary Summary
INRLF Chart
Similar
Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study
Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.
Valneva SE (VALN) Q3 2025 Earnings Call Transcript
Valneva SE ( VALN ) Q3 2025 Earnings Call November 20, 2025 9:00 AM EST Company Participants Joshua Drumm - Vice President of Investor Relations Thomas Lingelbach - President, CEO & Director Peter Buhler - Chief Financial Officer Conference Call Participants Vamil Divan - Guggenheim Securities, LLC, Research Division Maurice Raycroft - Jefferies LLC, Research Division Romy O'Connor - Van Lanschot Kempen NV Presentation Operator Good day, and thank you for standing by. Welcome to the Valneva 9 Months 2025 Financial Results Conference Call and Webcast.
Valneva SE (VALN) Q2 2025 Earnings Call Transcript
Valneva SE (NASDAQ:VALN ) Q2 2025 Earnings Conference Call August 12, 2025 9:00 AM ET Company Participants Joshua Drumm - Vice President of Investor Relations Peter Buhler - Chief Financial Officer Thomas Lingelbach - President, CEO & Director Conference Call Participants Damien Choplain - Stifel, formerly Bryan Garnier & Co., Research Division Mohamad Amin Makarem - Jefferies LLC, Research Division Rajan Sharma - Goldman Sachs Group, Inc., Research Division Sebastiaan van der Schoot - Unidentified Company Joshua Drumm Thank you, operator. Hello, and thank you for joining us to discuss Valneva's first half 2025 results and corporate update.
Valneva SE (INRLF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Valneva SE ever had a stock split?
Valneva SE Profile
| Biotechnology Industry | Healthcare Sector | Thomas Lingelbach CEO | OTC GREY Exchange | FR0004056851 ISIN |
| FR Country | 713 Employees | - Last Dividend | 15 Jan 2015 Last Split | - IPO Date |
Overview
Valneva SE is a pioneering specialty vaccine company hinged on the development, manufacturing, and commercialization of vaccines for infectious diseases that present significant unmet medical needs. With its inception in 1998, the company has rooted itself firmly in Saint-Herblain, France, and spans a vast distribution network covering the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, other European countries, and beyond on an international scale. Leveraging strategic collaborations, such as with Pfizer, Inc. for Lyme disease vaccine co-development and commercialization, and Instituto Butantan for chikungunya vaccine endeavors, Valneva stands at the forefront of vaccine innovation and public health advancement.
Products and Services
- IXIARO
An inactivated Vero cell culture-derived vaccine aimed at the active immunization against Japanese encephalitis, safeguarding individuals from this dangerous neurological infection.
- DUKORAL
A unique oral vaccine formulated for the deterrent of diarrhea attributable to Vibrio cholera and/or heat-labile toxin-producing enterotoxigenic Escherichia coli, promoting gastrointestinal wellness.
- IXCHIQ
A single-dose, live-attenuated vaccine designed to prevent diseases caused by the chikungunya virus, furnishing protection against this debilitating virus.
- VLA2001
An inactivated whole-virus COVID-19 vaccine, providing a form of active immunization against COVID-19, contributing to the global efforts in pandemic control.
- VLA15
A promising vaccine candidate currently in Phase III clinical trials, targeting Borrelia, the bacterium responsible for Lyme disease, reflecting Valneva's commitment to tackling tick-borne infections.
- VLA1553
Another Phase III clinical trial candidate, focused on combating the chikungunya virus, highlighting Valneva's continuous efforts in addressing viral diseases through innovative vaccine development.
- VLA1554
A vaccine candidate in the development stages aimed at human metapneumovirus, underscoring the company's dedication to expanding its vaccine portfolio to cover a wider range of infectious diseases.
- VLA2112
This candidate targets the treatment of patients with Epstein-Barr virus, indicating Valneva's strategic move towards developing vaccines for highly prevalent but less addressed viral infections.
